Find Clinical Drug Pipeline Developments & Deals for Tak-580

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tak-580

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Access Biotechnology

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing May 21, 2020

            Details:

            The company intends to use the funds to continue to expand development of its clinical-stage oncology treatment acquired through Takeda Pharmaceutical Company Limited.